Drug
Nirogacestat
Drug Profile
| Therapeutic Class | Targeted Therapy |
| Drug Class | Other Targeted Agents |
| Group | Gamma-secretase inhibitor |
| Mechanism of Action | Gamma-secretase inhibitor |
| Half-life | 23 h |
Study design
RT–Drug Timing Window
Study design
RT–Drug Timing Window
Radiobiological rationale for RT–drug interaction
Radiosensitizing in Notch-active tumors (↑DNA damage, ↓DNA-PK, ↓stem survival) (Mizugaki et al., British Journal of Cancer, 2012; Zhang et al., European Journal of Pharmacology, 2018). Notch is critical to GI and skin epithelial homeostasis, so a theoretical increase in in-field GI/mucocutaneous adverse events is plausible (GI adverse events are a known class effect).
Data on this page refer exclusively to patients treated with
Nirogacestat combined with SBRT, without concurrent use of
drugs from other classes.
Combination therapy data and pooled group-level evidence are available on the
Gamma-secretase inhibitor group page.